# Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

> **NCT02219789** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 10 (actual)

## Conditions studied

- Estrogen Receptor Positive
- Progesterone Receptor Positive
- Recurrent Breast Carcinoma
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** Alisertib
- **DRUG:** Fulvestrant
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02219789
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-05
- **Primary completion:** 2016-03-28
- **Final completion:** 2018-10-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02219789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02219789, "Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02219789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*